Skip to main content
Erschienen in: Pathology & Oncology Research 2/2020

13.06.2019 | Original Article

Comprehensive Data of P53 R282 Gene Mutation with Human Papillomaviruses (HPV)-Associated Oral Squamous Cell Carcinoma (OSCC)

verfasst von: Tipaya Ekalaksananan, Weerayut Wongjampa, Pensiri Phusingha, Jureeporn Chuerduangphui, Patravoot Vatanasapt, Supannee Promthet, Natcha Patarapadungkit, Chamsai Pientong

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Alterations of the P53 gene and human papillomavirus (HPV) infection are associated with development of oral squamous cell carcinoma (OSCC). We aimed to identify mutation of P53 exon 8 codon 282 in OSCC and correlate these with HPV infection as well as histopathological grade of OSCC. Samples of known HPV infection status were studied including oral lesion cells, formalin-fixed paraffin embedded (FFPE) tissues from OSCC and exfoliated oral cells of matched age-sex controls. P53 exon 8 mutation was detected using the polymerase chain reaction (PCR). Mutation of codon 282 was identified by allele-specific oligonucleotide typing (ASO) using EvaGreen real-time PCR. The PCR products were analyzed by gel electrophoresis and melting curve analysis. Mutation of P53 exon 8 was seen in 81.7% and 69.6% of FFPE OSCC tissues and oral lesion cells, respectively. This was significantly higher than in controls (16.7%). Frequency of mutation did not differ between HPV-positive samples (62.5% and 81.8% in oral lesion cells and FFPE tissue samples, respectively) and HPV-negative samples (73.3% and 81.5% in oral lesion cells and FFPE tissue samples, respectively). This finding is similar to P53 codon 282 mutation that was found only in FFPE tissues (35.0%) and oral lesion cells (32.6%) from both HPV-positive and negative OSCC. Interestingly, frequency of mutation was higher in well-differentiated OSCC with HPV-infection (28.1%) than without HPV (14.8%). This result demonstrated a mutation hot spot in P53 associated with oral carcinogenesis and might be useful to guide chemotherapeutic modality for HPV-associated OSCC in northeast Thailand.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Greenblatt M, Bennett WP, Hollstein M, Harris C (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed Greenblatt M, Bennett WP, Hollstein M, Harris C (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed
7.
13.
Zurück zum Zitat Lo K, Mok C, Chung G, Huang D, Wong F, Chan M, Lee J, Tsao S (1992) Presence of p53 mutation in human cervical carcinomas associated with HPV-33 infection. Anticancer Res 12:1989–1994PubMed Lo K, Mok C, Chung G, Huang D, Wong F, Chan M, Lee J, Tsao S (1992) Presence of p53 mutation in human cervical carcinomas associated with HPV-33 infection. Anticancer Res 12:1989–1994PubMed
14.
Zurück zum Zitat Phusingha P, Ekalaksananan T, Vatanasapt P, Loyha K, Promthet S, Kongyingyoes B, Patarapadungkit N, Chuerduangphui J, Pientong C (2017) Human papillomavirus (HPV) infection in a case-control study of oral squamous cell carcinoma and its increasing trend in northeastern Thailand. J Med Virol 89:1096–1101. https://doi.org/10.1002/jmv.24744 CrossRefPubMed Phusingha P, Ekalaksananan T, Vatanasapt P, Loyha K, Promthet S, Kongyingyoes B, Patarapadungkit N, Chuerduangphui J, Pientong C (2017) Human papillomavirus (HPV) infection in a case-control study of oral squamous cell carcinoma and its increasing trend in northeastern Thailand. J Med Virol 89:1096–1101. https://​doi.​org/​10.​1002/​jmv.​24744 CrossRefPubMed
19.
Zurück zum Zitat Chuerduangphui J, Pientong C, Patarapadungkit N, Chotiyano A, Vatanasapt P, Kongyingyoes B, Promthet S, Swangphon P, Bumrungthai S, Pimson C (2017) Amplification of EGFR and cyclin D1 genes associated with human papillomavirus infection in oral squamous cell carcinoma. Med Oncol 34:148. https://doi.org/10.1007/s12032-017-1010-6 CrossRefPubMed Chuerduangphui J, Pientong C, Patarapadungkit N, Chotiyano A, Vatanasapt P, Kongyingyoes B, Promthet S, Swangphon P, Bumrungthai S, Pimson C (2017) Amplification of EGFR and cyclin D1 genes associated with human papillomavirus infection in oral squamous cell carcinoma. Med Oncol 34:148. https://​doi.​org/​10.​1007/​s12032-017-1010-6 CrossRefPubMed
23.
Zurück zum Zitat Acharya S, Ekalaksananan T, Vatanasapt P, Loyha K, Phusingha P, Promthet S, Kongyingyoes B, Pientong C (2015) Association of Epstein-Barr virus infection with oral squamous cell carcinoma in a case–control study. J Oral Pathol Med 44:252–257CrossRef Acharya S, Ekalaksananan T, Vatanasapt P, Loyha K, Phusingha P, Promthet S, Kongyingyoes B, Pientong C (2015) Association of Epstein-Barr virus infection with oral squamous cell carcinoma in a case–control study. J Oral Pathol Med 44:252–257CrossRef
24.
32.
Zurück zum Zitat Sharan RN, Mehrotra R, Choudhury Y, Asotra K (2012) Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 7:e42759CrossRef Sharan RN, Mehrotra R, Choudhury Y, Asotra K (2012) Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 7:e42759CrossRef
33.
Zurück zum Zitat Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435CrossRef Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435CrossRef
34.
Zurück zum Zitat Scheidt JHG, Yurgel LS, Cherubini K, Figueiredo MAZ, Salum FG (2012) Characteristics of oral squamous cell carcinoma in users or non users of tobacco and alcohol. Revista Odonto Ciência 27:69–73CrossRef Scheidt JHG, Yurgel LS, Cherubini K, Figueiredo MAZ, Salum FG (2012) Characteristics of oral squamous cell carcinoma in users or non users of tobacco and alcohol. Revista Odonto Ciência 27:69–73CrossRef
36.
40.
Zurück zum Zitat Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, Fujinaga K, K-i N, Fukuda H (1996) Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 12:1663–1668PubMed Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, Fujinaga K, K-i N, Fukuda H (1996) Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 12:1663–1668PubMed
43.
Zurück zum Zitat Brandwein M, Zeitlin J, Nuovo G, MacConnell P, Bodian C, Urken M, Biller H (1994) HPV detection using “hot start” polymerase chain reaction in patients with oral cancer: a clinicopathological study of 64 patients. Mod Pathol 7:720–727PubMed Brandwein M, Zeitlin J, Nuovo G, MacConnell P, Bodian C, Urken M, Biller H (1994) HPV detection using “hot start” polymerase chain reaction in patients with oral cancer: a clinicopathological study of 64 patients. Mod Pathol 7:720–727PubMed
Metadaten
Titel
Comprehensive Data of P53 R282 Gene Mutation with Human Papillomaviruses (HPV)-Associated Oral Squamous Cell Carcinoma (OSCC)
verfasst von
Tipaya Ekalaksananan
Weerayut Wongjampa
Pensiri Phusingha
Jureeporn Chuerduangphui
Patravoot Vatanasapt
Supannee Promthet
Natcha Patarapadungkit
Chamsai Pientong
Publikationsdatum
13.06.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00673-6

Weitere Artikel der Ausgabe 2/2020

Pathology & Oncology Research 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.